Zoetis Inc.
Zoetis Inc. Announces Board Member Departure and Shareholder Votes on Governance Proposals
Summary
Zoetis Inc. announced that Dr. Linda Rhodes retired from the Board of Directors effective May 21, 2024, prior to the 2024 Annual Meeting of Shareholders. At the Annual Meeting held on May 22, 2024, shareholders approved an amendment to the Company's Restated Certificate of Incorporation to provide for the exculpation of certain officers. Additionally, shareholders elected twelve directors, approved the compensation program for named executive officers on a non-binding advisory basis, ratified the appointment of KPMG LLP as the independent registered public accounting firm, approved the Officer Exculpation Amendment, and rejected a shareholder proposal regarding the director resignation policy.
Profitelligence Alerts
Get alerts for ZTS
Be first to know when Zoetis Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Zoetis Inc.
Zoetis Inc. is a global leader in the animal healthcare sector, specializing in the development, manufacture, and commercialization of a diverse range of medicines and vaccines for pets and livestock. Originally part of Pfizer, Zoetis spun off in 2013 and has solidified its position as a key player in the industry. The company's portfolio includes products aimed at veterinarians and livestock producers, supporting health and productivity across various animal species. Zoetis's impact is significant in both the companion animal market, which is driven by increasing pet ownership and rising expenditure on pet care, and the livestock market, which benefits from enhancements in productivity and disease management. Zoetis operates in over 100 countries, continuously investing in research and innovation to address the evolving needs of animal health. Its strategic initiatives and partnerships contribute to building a sustainable future for the animal health industry, bolstering Zoetis’s reputation and relevance in the global market.
Official SEC Documents
Advertisement